Genenta Science S.p.A. stock surged after ANEMOCYTE partnership. Discover temferon's cancer trial updates and what’s next.

Genenta & Anemocyte ink partnership to advance off-the-shelf LVV Plasmid DNA production: Milan Monday, October 27, 2025, 14:00 Hrs [IST] Genenta Science, a pioneer company in immu ...

Genenta Science (NasdaqCM:GNTA) recently drew widespread attention after announcing an expanded partnership with Anemocyte, centered on advancing off-the-shelf lentiviral vector Plasmid DNA technology ...

An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

Investing.com -- 4basebio PLC (AIM:4BB) stock surged 6.9% on Monday after announcing that a global Tier 1 pharmaceutical partner has begun dosing patients in Phase I/II clinical trials using the ...

A new way to deliver protective antibodies against COVID-19 was tested in a Phase I clinical trial. Instead of injecting ...

Monday that a global tier-one pharmaceutical partner had started dosing patients in a phase one and two US clinical trial ...

Cambridge, UK, 27 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products announces that, following Investigational New Drug (IND) approval from the FDA, a ...

The Society for Immunotherapy of Cancer (SITC) received over 1,300 abstract submissions in 2025, and has announced titles and authors for the accepted Late-breaking Abstracts (LBA). Late-breaking ...

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...

PacBio, developer of advanced sequencing technologies, has announced innovations to its Revio and Vega platforms designed to ...